Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare two medications currently injected intra-operatively to help decrease pain after surgery in patients undergoing a primary total hip replacement (THR). The two medications are Exparel® (bupivacaine liposome injectable suspension) plus bupivacaine with epinephrine versus bupivacaine with epinephrine. This study is looking to see if one medication works better than the other in managing post-operative pain after THR. The study hypothesis is that Exparel® plus bupivacaine with epinephrine will demonstrate better pain management in THR patients post-operatively. Both medications are FDA-approved for post-operative analgesia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: American Hip Institute
• Treatments: Bupivacaine; Epinephrine; Epinephryl borate; Racepinephrine

Criteria

Inclusion Criteria:

• Patients scheduled to undergo primary unilateral total hip replacement

• Patients diagnosed with hip osteoarthritis

• Patients failed to improve with conservative measures

• Patients willing and able to sign informed consent

Exclusion Criteria:

• Revision total hip replacement

• Bilateral total hip replacement

• Birmingham hip resurfacing

• Patients with hepatic/kidney disease

• Patients with a known allergy to bupivacaine or other local anesthetics